T0901317 Inhibits Cisplatin-Induced Apoptosis in Ovarian Cancer Cells [Corrected]

Daniel H Miller, Andrew K Fischer, Katrina F Chu, Risa Burr, Sara Hillenmeyer, Laurent Brard, Alexander S Brodsky

Int J Gynecol Cancer. 2011 Nov;21(8):1350-6.

PMID: 21921802

Abstract:

Objective:




To determine the function of T0901317 in combination treatment with cisplatin in ovarian cancer cells.













Methods:




We screened the effects of 3 nuclear hormone receptor ligands on cell viability in a panel of ovarian cancer cell lines. T0901317 regulation of apoptosis and cell cycle regulators was determined when applied as a single agent or in combination with cisplatin.













Results:




Surprisingly, the liver X receptor agonist T0901317 had no significant effects on a panel of 7 ovarian cancer cell lines as a single agent. T0901317 does, however, significantly decrease cisplatin efficacy in at least 3 ovarian cancer cell lines. T0901317 reduces cisplatin-induced apoptosis and reverses cisplatin-induced expression of cell cycle regulators. T0901317 seems to work in a liver X receptor-, pregnane X receptor-, and farnesoid X receptor-independent manner, as agonists of these nuclear hormone receptors did not show similar effects. Interestingly, in the A2780-cp drug-resistant cell line, the effect of T0901317 is lost, suggesting that the pathways stimulated by T0901317 to reduce cisplatin efficacy could be inherently active features of the selected resistance.













Conclusions:




Together, these data suggest that T0901317 inhibits cisplatin in some ovarian cancer cells. These data provide an avenue to investigate when T0901317 may be acting to promote tumor survival and drug resistance through control of apoptosis and when it may be acting as an antitumor agent as has been previously reported.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP293754559	T0901317		293754-55-9	Price